Mallinckrodt plc(NYSE: MNK), a leading global specialty pharmaceutical company, is reporting interim data1 at the midway point of enrollment in the ongoing Phase 4, multicenter study assessing the efficacy and safety of H.P. Acthar Gel in patients with persistently active rheumatoid arthritis (RA) despite receiving disease-modifying anti-rheumatic drugs (DMARDs) and corticosteroids. The data will be reported in a poster presentation on Tuesday, Oct. 23 at the 2018 American College of Rheumatology/Association of Rheumatology Health Professionals (ACR/ARHP) Annual Meeting (Oct. 19-24) in Chicago, IL (see also Mallinckrodt plc).
Earlier at this year’s 2018 ACR/ARHP Annual Meeting, Mallinckrodt presented pre-clinical findings2 on the immune modulatory effect of H.P. Acthar Gel in a rat adjuvant-induced arthritis (AIA) model and the effect on osteoclast-mediated bone resorption compared to an immunosuppressive steroid.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.